Showing results (91-100 of 101) with videos related to
Sort By:
Pageof 11
The Lancet. Respiratory Medicine|October 17, 2022
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trialSantiago Ponce Aix, Tudor Eliade Ciuleanu, Alejandro Navarro, et al.European Journal of Cancer (Oxford, England : 1990)|April 10, 2026
Implementing a molecular prescreening strategy for tumors without public NGS access in a cancer center network: Results from the PREICO projectPaula Sàbat, Maria Ajenjo-Bauza, Cinta Hierro, et al.The Lancet. Respiratory Medicine|April 15, 2017
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trialRafael Rosell, Urania Dafni, Enriqueta Felip, et al.Scientific Reports|December 8, 2015
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancerNiki Karachaliou, Jordi Codony-Servat, Cristina Teixidó, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 13, 2019
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical TrialSebastian Michels, Bartomeu Massutí, Hans-Ulrich Schildhaus, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2021
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 TrialLuis G Paz-Ares, Suresh S Ramalingam, Tudor-Eliade Ciuleanu, et al.Lung Cancer (Amsterdam, Netherlands)|October 1, 2025
Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trialDolores Isla, Jon Zugazagoitia, Edurne Arriola, et al.Journal of the National Cancer Institute|April 5, 2017
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLCImane Chaib, Niki Karachaliou, Sara Pilotto, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2024
Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung CancerMelina Peressini, Rosario Garcia-Campelo, Bartomeu Massuti, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2025
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)James Chih-Hsin Yang, Mengzhao Wang, Ludovic Doucet, et al.Pageof 11